A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
← catalyst calendarNCT06845202 · readout in 376 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
105actual
Sites
22
Countries
Argentina, Canada, Chile +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-03 | actual | When the study began enrolling |
| Primary completion | 2027-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obese or Overweight Healthy Volunteers
- Type 2 Diabetes Mellitus (T2DM)
Interventions
- Drug: ALN-4324
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Frequency of Adverse Events (AEs)
measured Up to 9 months
Part B: Frequency of Adverse Events
measured Up to 12 months
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed